NanOlogy Welcomes Dr. John M. Goldberg as Chief Medical Officer to Drive Oncology Drug Development NanOlogy, a clinical-stage oncology company, has announced the appointment of Dr. John M. Goldberg as CMO to lead efforts in their investigative drug portfolio targeting pediatric brain cancer.

NanOlogy Welcomes Dr. John M. Goldberg as Chief Medical Officer to Drive Oncology Drug Development #United_States #Fort_Worth #oncology #NanOlogy #John_M._Goldberg

NanOlogy Appoints David J. Arthur as New CEO to Enhance Drug Development Efforts David J. Arthur has been appointed as the Chief Executive Officer of NanOlogy, LLC, where he will lead the charge in drug development strategies and initiatives focused on pediatric brain cancer.

NanOlogy Appoints David J. Arthur as New CEO to Enhance Drug Development Efforts #United_States #Fort_Worth #NanOlogy #David_Arthur #LSAM

NanOlogy Launches Innovative Drug Program for Pediatric Brainstem Tumor NanOlogy introduces a groundbreaking drug development initiative targeting DIPG, a rare and aggressive pediatric brain tumor, aiming for clinical trials by late 2026.

NanOlogy Launches Innovative Drug Program for Pediatric Brainstem Tumor #United_States #Fort_Worth #DIPG #NanOlogy #CISPLATIN